Developing a novel, safe drug to prevent heart attacks, strokes, and liver transplants from NASH
- Security Type
- Min Investment
New York, NY
- Offering Date
- October 18, 2021
- Expected Close Date
- January 16, 2022
Use of Proceeds
- Legal, accounting, market research
- Toxicology studies
Key Deal Facts
CEO designed trials for Vascepa®, which reduces heart attack and stroke risk for high triglycerides.
Awarded $700k from Dutch government to perform more studies on our drug Corvida™'s potential.
Results of Corvida™'s affect on genes associated with atherosclerosis due in 2022.
Funds raised will lead to PreIND meetings with the FDA to ensure acceptability of human trials.
Corvida™'s components are designated GRAS (Generally Regarded as Safe) by the FDA.
Corvida™ is protected by patents in the US and Japan and are owned by the company.
This is an opportunity for you to impact global health and potentially realize significant financial gains.
A SAFE is an agreement between you—the investor—and the company in which the company promises to give you a future equity stake based on the amount you invested. It also involves some kind of a triggering event that must take place in order for you to get your future equity stake. Be careful as you may only get equity if a particular event is triggered.
No reports have been submittedBecome a Reporter